Bavarian Nordic, a Danish biotech company, is transitioning from a government contract-reliant vaccine manufacturer to a commercial vaccine giant. Despite late-stage stumbles, the company remains confident in its future strategy and plans to submit a chikungunya vaccine for FDA approval. Bavarian Nordic recently acquired travel vaccine portfolios from GSK and Emergent BioSolutions and is focused on building a more traditional commercial infrastructure. The company's chikungunya vaccine has shown promising results in phase 3 trials and is expected to become a brand of choice for travelers to Asia and South America.

Bavarian Nordic's Vaccine Transformation